These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 23648018)

  • 1. Sudden cardiac arrest in a young patient with hypertrophic cardiomyopathy and zero canonical risk factors: the inherent limitations of risk stratification in hypertrophic cardiomyopathy.
    Kohorst JJ; Bos JM; Hagler DJ; Ackerman MJ
    Congenit Heart Dis; 2014; 9(2):E51-7. PubMed ID: 23648018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy.
    Miller MA; Gomes JA; Fuster V
    Nat Clin Pract Cardiovasc Med; 2007 Dec; 4(12):667-76. PubMed ID: 18033231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certification of competitive sports participation of a professional soccer player with hypertrophic cardiomyopathy and implanted ICD.
    Laszlo R; Steinacker JM
    Clin Res Cardiol; 2016 Aug; 105(8):710-713. PubMed ID: 27003691
    [No Abstract]   [Full Text] [Related]  

  • 8. Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features.
    Bongioanni S; Spirito P; Masi AS; Chiribiri A; Bonamini R; Conte MR
    Circ Cardiovasc Imaging; 2009 Jul; 2(4):349-50. PubMed ID: 19808616
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ
    Circ J; 2010 Nov; 74(11):2271-82. PubMed ID: 20962423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypertrophic cardiomyopathy and sudden cardiac death--ICD indications in the margin of uncertainty].
    Fauchère I; Duru F
    Praxis (Bern 1994); 2009 Aug; 98(17):941-52. PubMed ID: 19711287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. My approach to clinical management of hypertrophic cardiomyopathy.
    Maron MS
    Trends Cardiovasc Med; 2014 Oct; 24(7):314-5. PubMed ID: 25218674
    [No Abstract]   [Full Text] [Related]  

  • 12. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.
    Dinshaw L; Münch J; Dickow J; Lezius S; Willems S; Hoffmann BA; Patten M
    Clin Res Cardiol; 2018 Feb; 107(2):130-137. PubMed ID: 28965260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Athletes with implantable cardioverter defibrillators: can they return to competitive sports?
    Prutkin JM; Ackerman MJ; Drezner JA
    Heart; 2016 Jan; 102(2):93-4. PubMed ID: 26729607
    [No Abstract]   [Full Text] [Related]  

  • 15. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
    Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R
    J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy.
    Maron BJ
    Cardiol Rev; 2002; 10(3):173-81. PubMed ID: 12047795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can sudden cardiac death be prevented?
    Maron BJ
    Cardiovasc Pathol; 2010; 19(6):329-35. PubMed ID: 20378375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy.
    Maron BJ; Estes NA; Maron MS; Almquist AK; Link MS; Udelson JE
    Circulation; 2003 Jun; 107(23):2872-5. PubMed ID: 12814983
    [No Abstract]   [Full Text] [Related]  

  • 19. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
    Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.